In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier for C-2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers - Publication - Bridge of Knowledge

Search

In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier for C-2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers

Abstract

Traditional small-molecule chemotherapeutics usually do not distinguish tumors from healthy tissues. However, nanotechnology creates nanocarriers that selectively deliver drugs to their site of action. This work is the next step in the development of the quantum dot−β−cyclodextrin−folic acid (QD−β−CD−FA) platform for targeted and selected delivery of C−2028 unsymmetrical bisacridine in cancer therapy.Herein, we report an initial biological evaluation (using flow cytometry and light microscopy) as well as cell migration analysis of QD−β−CD(C−2028)−FA nanoconjugate and its components in the selected human lung and prostate cancer cells, as well as against their respective normal cells. C−2028 compound induced apoptosis, which was much stronger in cancer cells compared to normal cells. Conjugation of C−2028 with QDgreen increased cellular senescence, while the introduction of FA to the conjugate significantly decreased this process. C−2028 nanoencapsulation also reduced cell migration. Importantly, QDgreen and QDgreen−β−CD−FA themselves did not induce any toxic responses in studied cells. In conclusion, the results demonstrate the high potential of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier (QDgreen−β−CD−FA) for drug delivery in cancer treatment. Nanoplatforms increased the amount of delivered compounds and demonstrated high suitability.

Citations

  • 0

    CrossRef

  • 0

    Web of Science

  • 0

    Scopus

Authors (8)

Cite as

Full text

download paper
downloaded 44 times
Publication version
Accepted or Published Version
DOI:
Digital Object Identifier (open in new tab) 10.1007/s43440-024-00606-4
License
Creative Commons: CC-BY open in new tab

Keywords

Details

Category:
Articles
Type:
artykuły w czasopismach
Published in:
Pharmacological Reports no. 76, pages 823 - 837,
ISSN: 1734-1140
Language:
English
Publication year:
2024
Bibliographic description:
Pilch J., Potęga A., Kowalik P., Kowalczyk A., Bujak P., Kasprzak A., Paluszkiewicz E., Nowicka A. M.: In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot−β−cyclodextrin carrier for C-2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers// Pharmacological Reports -Vol. 76, (2024), s.823-837
DOI:
Digital Object Identifier (open in new tab) 10.1007/s43440-024-00606-4
Sources of funding:
Verified by:
Gdańsk University of Technology

seen 79 times

Recommended for you

Meta Tags